In insulin-treated type 1 diabetes, canagliflozin increased diabetic ketoacidosis

Annals of Internal Medicine

Volumn 165, Issue 2, 2016, Pages JC2-

  Sfeir, Jad G ^a   Montori, Victor M ^a   Peters, A ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; HEMOGLOBIN A1C; INSULIN; PLACEBO; ANTIDIABETIC AGENT;

ADD ON THERAPY; ADULT; AGED; BODY MASS; CONTROLLED STUDY; DIABETIC COMA; DIABETIC KETOACIDOSIS; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HOSPITALIZATION; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INTENTION TO TREAT ANALYSIS; KETONURIA; MAJOR CLINICAL STUDY; METABOLIC ACIDOSIS; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 1; DIABETIC KETOACIDOSIS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 84979570853     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/ACPJC-2016-165-2-002     Document Type: Note

References (3)

1. Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care. 2015;38:2258-65.
2. Cefalu WT. Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition. J Clin Invest. 2014;124:485-7.
3. Taborsky GJ Jr. The physiology of glucagon. J Diabetes Sci Technol. 2010; 4:1338-44.